Inflammation is an essential part of the body's defense system, helping protect against infections and respond to injury. However, when immune activity becomes excessive or continues unnecessarily, it can contribute to autoimmune diseases in which the immune system mistakenly attacks healthy tissues.

Researchers at Boston Children's Hospital have identified an unexpected way immune cells transmit inflammatory signals, potentially revealing a new target for future treatments.

A Different Way for Immune Cells to Communicate

For decades, scientists have understood immune signaling largely through receptors, specialized proteins that detect external signals and initiate responses inside cells. A new study published in Nature in September 2026 has revealed that certain inflammatory signals can continue through a different mechanism, even after separating from the receptors that initially activated them.

The research team, led by Jonathan Kagan at Boston Children's Hospital, investigated Toll-like receptors (TLRs). These proteins help the immune system recognize signs of infection and activate defensive responses. When TLRs detect a threat, they normally recruit proteins inside the cell to transmit instructions that regulate inflammation.

The researchers observed that the signaling process could continue after certain proteins separated from the receptors. Rather than simply ending the response, this separation enabled the proteins to assemble into a complex called the myddosome. This finding challenges the conventional understanding of how inflammatory signals are transmitted. It suggests that the receptors responsible for detecting threats may not be the only important targets when attempting to control excessive immune activity.

Why the Myddosome Matters

The myddosome is a molecular assembly that helps activate genes involved in inflammation. Once formed, it supports the signaling processes that prompt cells to produce inflammatory substances and coordinate immune responses. The research team found that the assembly of this complex depended on signaling proteins being released from the receptors. When this release was prevented, the myddosome could not form properly, and the activation of inflammatory genes was disrupted.

This distinction could have important implications for drug development. Instead of concentrating exclusively on blocking receptors, scientists may be able to interfere with the molecular machinery responsible for carrying inflammatory instructions forward. The approach could be especially relevant when receptor-blocking strategies fail to provide sufficient control over inflammation.

Expert Insight

Jonathan Kagan, Ph.D., senior author of the study, director of basic research, and Shwachman Chair in Gastroenterology at Boston Children's Hospital, emphasized the broader scientific significance of the discovery. Kagan stated: “The discovery of this receptor-free signal transduction underscores the value of exploratory science as a means to expand the lexicon of life.”

Early Evidence for Future Therapies

The researchers reported pharmacological evidence that disrupting myddosome activity reduced inflammation in mice. This finding strengthens the possibility that the complex could serve as a target for future treatments. Autoimmune conditions can involve persistent immune activation that damages healthy tissues.

A treatment that selectively modifies inflammatory signaling could eventually help control these responses. However, the current research does not establish that a myddosome-targeting medicine is safe or effective in humans. Further studies must determine how the pathway behaves across different diseases, whether it can be targeted without weakening normal immune defenses, and which compounds could achieve the desired effect.

Inflammation also plays an important role in fighting infections and repairing damaged tissue. Therefore, future therapies would need to control harmful activity without unnecessarily suppressing protective responses.

What the Discovery Means for Medical Research

The findings provide a new framework for understanding how immune cells coordinate inflammatory activity. They also encourage researchers to examine signaling proteins after they separate from their original receptors, rather than assuming that receptor activation alone determines the entire response.

Although clinical applications remain uncertain, the discovery may help guide the development of more precise treatments for autoimmune and other inflammatory conditions. Its greatest immediate value lies in identifying a previously overlooked mechanism that scientists can now investigate in greater detail.

The 2026 study from Boston Children's Hospital reveals that inflammatory signaling can continue through a receptor-free mechanism involving the formation of myddosomes. Experiments in mice suggest that disrupting this molecular complex may reduce inflammation, creating a promising direction for therapeutic research.

Further investigation is necessary before this approach can be used in clinical care. Nevertheless, the discovery expands scientific understanding of immune communication and provides a potential foundation for developing more targeted ways to manage harmful inflammation.